Annual Report FY26: Revenue up 24.5%, PAT rises 29% post BSE SME listing

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+3.0%1-day move

₹180.00

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————+3.0+1.7-1.3-2.2-0.9-0.6+0.4+1.7——

Up moveDown movePending

AI summary

Mahamaya Lifesciences filed its first annual report as a listed company after BSE SME listing on Nov 18, 2025. Revenue from operations rose 24.5% to Rs 328.87 crore, EBITDA grew 32.6% to Rs 34.26 crore with margin expanding to 10.42% from 9.78%, and PAT climbed 29% to Rs 16.52 crore. Basic EPS improved to Rs 8.33. Net debt-equity ratio improved to 0.74x from 1.18x after the Rs 70.44 crore IPO. No dividend declared. IPO proceeds deployment extended into FY27 and FY28 for technical manufacturing plant and facility expansion.

Likely market impact

Strong post-listing debut performance with healthy growth, margin expansion and balance sheet strengthening, supportive for stock sentiment.